Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Uropartners LLC

Neither a doctor nor a teaching hospital

Research payments

$1,909,899

168 payments

Through program year 2025, Uropartners LLC is reported as receiving $1,909,899 in research payments, across 168 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $1,006,691 98
2024 Research $747,943 59
2023 Research $42,000 1
2020 Research $51,519 4
2019 Research $61,746 6

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $1,571,682 90 payments
  2. Sumitomo Pharma America, Inc. $179,939 54 payments
  3. Pfizer Inc. $99,988 4 payments
  4. Dendreon Pharmaceuticals LLC $49,177 14 payments
  5. Ortho-Clinical Diagnostics, Inc. $9,113 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) $1,276,887 60 payments
  2. A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc $253,446 23 payments
  3. A Multi-Center, Prospective, Observational Study of Patients Being Treated With Orgovyx $149,559 44 payments
  4. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib in Combination With Physicians Choice of Enzalutamide Or Abiraterone Acetateprednisone in Metastatic Castrationresistant Prostate Cancer With Dna Damage Repair Deficiencies $96,988 3 payments
  5. ProvONE Study $35,900 8 payments
  6. Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (Replace-Cv) $30,379 10 payments
  7. Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions $22,540 3 payments
  8. A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy $18,809 4 payments
  9. Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer Provent $11,016 3 payments
  10. VITROS Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection $9,113 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record